INCIPIT technology allowed the implementation of a multifunctional, micro-structured and electroconductive therapeutic product to treat patients with myocardial infarction, the leading cause of death for cardiovascular disease. Current therapies (drugs, bypass, angioplasty) do not restore the functionality of damaged myocardial tissue. INCIPIT technology aim is to stimulate the autonomous regeneration of myocardium and to protect the tissue against ventricular remodeling using advanced nanotechnologies. The in vivo approach, on which our technology is based, is the scientific option that poses the most ambitious challenges, but it is also the most attractive option for the market of smart therapies in cardiovascular field. The absence of an in vitro culture phase presents a series of advantages that makes this specific solution extremely attractive and faster to the biomedical industry.
The main step of innovation consists in the development of bioartificial, microstructured and electroconductive scaffolds able to induce stem cell commitment to a cardiac phenotype thanks to an optimal synergy among physico-chemical, electromechanical and structural characteristics. The innovation regards also the use of advanced nanotechnologies able to recruit endogenous stem cells and to prevent cardiac dysfunction after myocardial infarction. The cardiac patches currently available on the market offer mechanical support but are not able to provide biologically active and regenerative properties. INCIPIT technology offers a multifunctional approach in terms of mechanical support, regenerative action and reduction of ventricular remodeling.